openPR Logo
Press release

Presbyopia Pipeline Assessment Report 2025 | DelveInsight

08-11-2025 05:41 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Pre-Eclampsia Pipeline

Pre-Eclampsia Pipeline

DelveInsight's, "Presbyopia Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the Presbyopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Presbyopia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Presbyopia Pipeline. Dive into DelveInsight's comprehensive report today! @ Presbyopia Pipeline Outlook- https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Presbyopia Pipeline Report
• In June 2025, Ocuphire Pharma Inc. announced a Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia.
• In June 2025, Orasis Pharmaceuticals Ltd. conducted a study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.
• DelveInsight's Presbyopia Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Presbyopia treatment.
• The leading Presbyopia Companies such as Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio and others.
• Promising Presbyopia Pipeline Therapies such as Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.

Stay ahead with the most recent pipeline outlook for Presbyopia. Get insights into clinical trials, emerging therapies, and leading companies with Presbyopia @ Presbyopia Treatment Drugs- https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Presbyopia Emerging Drugs Profile
• LNZ100: Lenz Therapeutics
LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, a selective muscarinic receptor agonist. It works by constricting the pupil, creating a pinhole effect that improves near vision. Unlike other pupil-constricting agents, aceclidine has a unique mechanism of action that decouples the miotic effect from the stimulation of the ciliary muscle, reducing the risk of myopic shift and accompanying brow ache. This allows LNZ100 to provide a broad patient population with a long-lasting and efficient treatment for presbyopia, a condition characterized by the gradual hardening of the lens and decline in near vision with age. US Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for LNZ100 for the treatment of presbyopia. Currently, the drug is in registration stage of its clinical trial for the treatment of presbyopia.

• GLK-302: Glaukos Corporation
Glaukos Corporation is developing GLK-302, a sterile ophthalmic topical cream containing the active ingredient pilocarpine, for the treatment of presbyopia. GLK-302 is designed to be applied to the eyelid, allowing the pilocarpine to be delivered through the dermis to the eye. The mechanism of action involves pilocarpine, a muscarinic acetylcholine receptor agonist, which acts on the M3 and M1 receptors in the eye to cause pupillary constriction and increase the depth of focus, thereby improving near visual acuity in presbyopic patients without significantly deteriorating distance vision. Currently, the drug is in Phase II stage of its clinical trial for the treatment of presbyopia.

The Presbyopia Pipeline Report Provides Insights into-
• The report provides detailed insights about companies that are developing therapies for the treatment of Presbyopia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Presbyopia Treatment.
• Presbyopia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Presbyopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Presbyopia market

Explore groundbreaking therapies and clinical trials in the Presbyopia Pipeline. Access DelveInsight's detailed report now! @ New Presbyopia Drugs- https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Presbyopia Companies
Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio and others.

Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Presbyopia Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Unveil the future of Presbyopia Treatment. Learn about new drugs, Presbyopia Pipeline developments, and key companies with DelveInsight's expert analysis @ Presbyopia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Presbyopia Pipeline Report
• Coverage- Global
• Presbyopia Companies- Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio and others.
• Presbyopia Pipeline Therapies- Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.
• Presbyopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Presbyopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Presbyopia Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Presbyopia Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Presbyopia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Presbyopia - DelveInsight's Analytical Perspective
7. Late Stage Products (Registration)
8. LNZ100: Lenz Therapeutics
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. GLK-302: Glaukos Corporation
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Preclinical Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report.....
18. Inactive Products
19. Presbyopia - Collaborations Assessment- Licensing / Partnering / Funding
20. Presbyopia - Unmet Needs
21. Presbyopia - Market Drivers and Barriers
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Presbyopia Pipeline Assessment Report 2025 | DelveInsight here

News-ID: 4139198 • Views:

More Releases from DelveInsight Business Research LLP

Cutaneous T-Cell Lymphoma Pipeline Insights Report 2025: In-Depth Analysis of R&D Landscape, Targeted Therapies, and Strategic Developments Driving Oncology Drug Discovery
Cutaneous T-Cell Lymphoma Pipeline Insights Report 2025: In-Depth Analysis of R& …
DelveInsight's "Cutaneous T-cell lymphoma Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Non-Small Cell Lung Cancer Pipeline Drugs Report 2025: Unveiling the Next-Generation Therapies, Technological Advancements, and Clinical Innovations
Non-Small Cell Lung Cancer Pipeline Drugs Report 2025: Unveiling the Next-Genera …
DelveInsight's, Non-Small-Cell Lung Cancer (NSCLC) Pipeline Insights 2025" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Download our comprehensive
Acute Lymphocytic Leukemia Pipeline 2025: Key Insights into Novel Mechanisms, Ongoing Clinical Studies, and Future Treatment Paradigms Shaping the Oncology Market
Acute Lymphocytic Leukemia Pipeline 2025: Key Insights into Novel Mechanisms, On …
DelveInsight's "Acute Lymphocytic Leukemia Pipeline Insight 2025" report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Multiple Myeloma Pipeline Outlook Report 2025: A Comprehensive Review of Drugs in Development, Clinical Trials, and Breakthrough Strategies
Multiple Myeloma Pipeline Outlook Report 2025: A Comprehensive Review of Drugs i …
DelveInsight's "Multiple Myeloma Pipeline Insights 2025" report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights

All 5 Releases


More Releases for Presbyopia

Rising Geriatric Population Fuels Growth Of Myopia And Presbyopia Treatment Mark …
The Myopia and Presbyopia Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Myopia and Presbyopia Treatment Market Size and Projected Growth Rate? The market size for myopia and presbyopia treatment has witnessed substantial growth over several recent years. The market is projected
Presbyopia Treatment Market Trends And Industry Forecast 2024-2031
Presbyopia Treatment Market: Trends Shaping the Industry The presbyopia treatment market is experiencing significant growth, driven by a surge in the global aging population. As people live longer, the demand for effective solutions to age-related vision problems like presbyopia increases. This trend is fueling research and development efforts, leading to the introduction of innovative therapeutics like advanced contact lenses and eye drops. Market Segmentation: Addressing Diverse Needs The presbyopia treatment market is segmented
Presbyopia Treatment Market Growth Analysis 2023-2030
Global Presbyopia Treatment Market Gains Momentum Amidst Rising Aging Population and Innovations in Therapeutics: The global presbyopia treatment market has witnessed substantial growth in recent years, fueled by the increasing prevalence of presbyopia and the expanding aging population. Presbyopia, a common vision loss associated with aging, has prompted a surge in demand for effective treatments, leading to advancements in eyeglasses, contact lenses, surgeries, eye drops, and nutrient-based interventions. Refractive surgeries, including Conductive
Presbyopia Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companie …
DelveInsight's, "Presbyopia Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key takeaways from the Presbyopia Pipeline Insight Report • Presbyopia Pipeline report offers a comprehensive
Presbyopia Market 2020-2027 Sets the Table for Continued Growth || Top Growing C …
A transparent research method has been accomplished with the right tools and techniques to make this Presbyopia Market research report world-class. Two of the most widely used techniques namely SWOT analysis and Porter's Five Forces Analysis have been used while generating this report. Competitive analysis conducted in this report puts light on the moves of the key players in the Healthcare industry such as new product launches, expansions, agreements, joint
Asia-Pacific Presbyopia Correction Device Market Report 2017
MarketResearchReports.Biz presents this most up-to-date research on "Asia-Pacific Presbyopia Correction Device Market Report 2017" Description In this report, the Asia-Pacific Presbyopia Correction Device market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share